



COPY OF PAPERS  
ORIGINALLY FILED

Please type a plus sign (+) inside this box → [ + ]

PTO/SB/2 (03-00)

Approved for use through 10/31/2002. OMB 065-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED  
MAR 01 2002  
TECHNICAL CENTER 1600/2900

RECEIVED

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/666,481	
	Filing Date	September 20, 2000	
	First Named Inventor	Masayuki MORITA et al.	
	Group Art Unit	1626	
	Examiner Name	Laura L. Stockton	
Total Number of Pages in This Submission		Attorney Docket Number	740250-821

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Other
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	<u>Donald R. Studebaker, Reg. No. 32,815</u> Nixon Peabody LLP 8180 Greensboro Drive Suite 800 McLean, VA 22102
Signature	
Date	February 6, 2002

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <u>2-6-02</u>	
Type or printed name	Jeannie Saxton
Signature	
Date	February 6, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of  
Masayuki MORITA et al.

Serial No. 09/666,481

Filed: September 20, 2000

For: METHOD FOR PRODUCING

2-ALKYL-4-ISOTHIAZOLINE-3

ONE



Art Unit: 1626

Examiner: Laura L. Stockton, Ph.D

TECH CENTER 1600/2900

MAR 01 2002

RECEIVED

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on 2-6-02

*[Signature]*

AMENDMENT

Honorable Commissioner of Patents  
Washington, D.C. 20231


Sir:

In response to the Office Action dated December 3, 2001 please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend claims 1, 4, 8, 12, and 16 to read as follows:

A 1 1. (Amended). A method of producing 2-alkyl-4-isothiazoline-3-one represented by the general formula (III),



wherein the compound represented by formula (I),

